Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.32 |
| ▸ | ATF1 | P18846 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | IL1B | P01584 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | JUN | P05412 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31624742 | 0.84 | NFKB1 (0.37) | NFKB1ATF1L3MBTL1GABRB3NPSR1 | |
| SCHEMBL31624758 | 0.84 | NFKB1 (0.35) | AGBL2NFKB1ATF1L3MBTL1GABRB3 | |
| SCHEMBL31624864 | 0.82 | HPGD (0.38) | NFKB1ATF1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL30375350 | 0.79 | IL1B (0.35) | NFKB1ATF1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL26093672 | 0.79 | IL1B (0.35) | NFKB1ATF1L3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL31624863 | 0.78 | ATF1 (0.31) | NFKB1ATF1 | |
| SCHEMBL31405061 | 0.75 | IL1B (0.45) | IL1B | |
| SCHEMBL31624819 | 0.75 | IL1B (0.30) | IL1B | |
| SCHEMBL26093443 | 0.75 | ALOX5AP (0.36) | L3MBTL1NPSR1IL1B | |
| SCHEMBL31624772 | 0.74 | PPARD (0.31) | AGBL2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128777-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250195511-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195511-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | NLRP3, FABP3, NOD1 | AGBL2 2145/4885NFKB1 3142/4885ATF1 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.